The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population
Paroxetine Extended-Release Tablets USP, 25 mg and 37.5 mg, are indicated for the treatment of major depressive disorder
BIL also holds an option to increase its equity stake by an additional 15%
IND application for EB-003 expected in early 2026
Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
Subscribe To Our Newsletter & Stay Updated
